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The authors evaluated the data of 30 patients with cystic fibrosis (18 male, 12 female),
between ages 218 (average age: 9.57 years). In 60% of the patients serum cholesterol was below
the 5th percentile value according to the data of the NATIONAL CHOLESTEROL EDUCATION
PROGRAM (1991). They examined the connection between the serum cholesterol levels and the
total fat, fatty acids and cholesterol intake. No significant differences were found between total
fat, fatty acids and cholesterol intake of patients with serum cholesterol levels below the 5th
percentile value and patients with levels above the 5th percentile value. The analysis of the
nutritional data showed that lipid intake was in accordance with the proportion prescribed for
patients with CF (35.56% of energy). The intakes of saturated fatty acids (SFA), monounsaturated
fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) were 11%, 11% and 8,3% of total
energy, respectively, the PUFA/SFA ratio was 0.78. The ratio of linoleic to alfa-linolenic acid was
especially high: 29. The clinical condition of the patients in the low cholesterol level group, as
shown by the Shwachman-Kulczycki score was significantly lower (P<0.05) than that of the group
with serum cholesterol levels above the 5th percentile value. The authors therefore suggest the
importance of the regular monitoring of serum cholesterol levels in patients with cystic fibrosis.
Observing the changes in serum cholesterol levels is a fast, informative and inexpensive method
of evaluating the clinical course of the disease.
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Cystic fibrosis (CF) is one of the most common life-threatening, metabolic
diseases with an autosomal recessive pattern of inheritance. There is virtually no other
chronic disease, where the nutritional state plays such a crucial role in the progression
(ROULET, 1994). The fate of patients with CF is determined mainly by the state of their
lungs (BEDDOES et al., 1981; DODGE, 1992). It has been conclusively proven that
adequate nutritional state slows the progression of the pulmonary process and results in
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increased life expectancy and better life conditions for the patients (ANTHONY et al.,
1998.; MIETTIEN, 1972.; ROULET, 1994.). This is why physicians treating CF patients
place special emphasis on the evaluation of the nutritional state and related issues
(CABRERA et al., 1994; CANNELA et al.,1993, MARCUS et al., 1991; PLATA-SALAMÁN,
1996; SÓLYOM, 1996).
The aim of our study was to examine the cause and clinical significance of the
decreased levels of serum cholesterol seen in patients with CF. We compared the
nutrients intake  focusing on total fat, fatty acids and cholesterol  of patients with low
levels of serum cholesterol and patients with serum cholesterol level above the 5th
percentile value.
1. Methods
The study was carried out on 30 patients (18 male, 12 female) between 1 and 18
years of age (average age: 9.57 years) with cystic fibrosis, recruited from the outpatient
department for a scheduled follow up visit. All patients and their parents volunteered for
the study, which had been accepted by the ethical committee of Haynal Imre University
of Health Sciences. The disease was diagnosed based on the clinical signs and the
elevated levels of sweat chloride (>60 mmol l1); all of the patients underwent mutation
studies (Table 1).
The clinical condition of the patients was evaluated with the Shwachman-
Kulczycki score (SHWACHMAN & KULCZYCKI, 1958). As the analysis of stool lipid
excretion was not feasible for all of the children involved in the study, the dosage of the
enzyme substitution was set ensure one or maximum two stools of normal consistency
daily. The average lipase intake of our patients was ~5000 IU kg1/day.
Table 1
Mutations of cystic fibrosis patients (n=30)
Number of patients Mutation
15 ∆F508/∆F508
4 ∆F508/N
2 ∆F508/R553X
2 ∆F508/G542X
1 R553X/N
1 N/W1282X
5 N/N
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Participants had previously received three questionnaires prepared for recording
meals consumed on 2 weekdays and on the last Sunday before the examination. The
method of 3×24 h dietary record has been applied together with 1×24 h recall made by a
trained dietitian. The energy and nutrient intakes were calculated on the basis of the
nutrient data bank and computer program, both developed by the National Institute of
Food Hygiene and Nutrition (BÍRÓ et al., 1996., GANJI et al., 1998).
Laboratory measurements were performed as follows:
 Hepatic enzymes, alkaline phospatase, albumin were measured on a Hitachi 704
clinical analyzer with commercially available kits.
 Total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, Apo A, Apo
B concentrations were measured with Roche analytical kits with a Cobas Mira Plus
analyzer.
Statistical analysis was performed with the SPSS software program: means were
calculated for all values, comparison was performed with the ANOVA method
(significance level P<0.05) and linear regression was calculated (significance level
P<0.05).
2. Results
Table 2 summarizes the most important clinical data and nutrient intake of the
children involved in the study. The children were assigned to one of two groups based
on their serum cholesterol level (Table 3). Group 1 consisted of patients whose serum
cholesterol level was above the 5th percentile value for their age group and sex. Group 2
consisted of patients, whose serum cholesterol level did not reach the 5th percentile
value (NATIONAL CHOLESTEROL EDUCATION PROGRAM, 1991).
The analysis of the two groups reveals the following:
 there was no significant difference between values of the body mass index
 the Shwachman-Kulczycki score, indicative of the clinical condition of the
patient was significantly higher in children, whose level of serum cholesterol was above
the 5th percentile norm (P<0.05)
 there was no significant difference between the two groups in total energy, fat-,
cholesterol-, carbohydrate and protein energy intake,
 PUFA, MUFA- and SFA-energy percentages of the two groups did not show
significant differences either,
 PUFA/SFA ratio was 0.78,
 ratio of linoleic acid to alfa-linolenic acid was exceptionally high: 29,
 the intake of fibers was 23 g.
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Table 2
Some clinical data and nutrient intake of cystic fibrosis patients with different serum cholesterol levels
Clinical data and nutrient Group 1 Group 2
intake n=12 n=18
Mean ±SD Mean ±SD
Age (year) 9.6 3.15 9.6 3.67
Body mass index (BW kg m2) 15 1.91 16 3.13
Shwachman-Kulczycki score 89.2 12.03a 81.1 8.50a
Energy (kcal BW kg1) 105.7 32.22 104.6 32.70
Cholesterol (mg) 408 206.2 376 95.5
Cholesterol (mg BW kg1) 14.7 4.29 15.1 5.54
Fat % of energy 35.6 3.26 35.5 3.68
Carbohydrate % of energy 49 3.5 49 4.0
Protein % of energy 15.1 1.85 15.5 2.08
PUFA % of energy 7.8 1.77 8.8 2.52
MUFA % of energy 11.1 1.91 10.5 1.61
SFA % of energy 11.7 1.90 11.1 2.15
P/S 0.7 0.23 0.8 0.40
Fibers (g) 25.3 5.81 22.4 7.06
Linoleic acid (g) 22.4 7.23 24.2 7.43
α-Linolenic acid (g) 0.9 0.34 0.8 0.27
Linoleic/α-Linolenic acid 26 8.2 33 13.2
Means followed by the same letters are significantly different at P<0.05 level between the columns
Group 1: serum cholesterol level >5th percentile
Group 2: serum cholesterol level <5th percentile
Table 3
Serum total cholesterol 5th percentil levels according to the National
cholesterol Education Program, (1991), USA
Age Serum total cholesterol level
(year) (mmol l1)
Males Females
04 3.03 2.97
59 3.20 3.36
1014 3.18 3.28
1519 2.98 3.18
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Table 4
Biochemical indices of cystic fibrosis patients with different serum cholesterol levels
Biochemical indices Group 1 Group 2
n=12 n=18
Mean ±SD Mean ±SD
Serum cholesterol (mmol l1) 3.9 0.53b 2.7 0.38b
Serum HDL-cholesterol (mmol l1) 1.2 0.29b 0.9 0.20b
Serum LDL-cholesterol(mmol l1) 2.2 0.58b 1.3 0.37b
Serum ApoA (g l1) 1.4 0.22a 1.2 0.19a
Serum ApoB (g l1) 0.7 0.12b 0.6 0.09b
Serum triglycerides (mmol l1) 1.0 0.38 0.8 0.36
Serum uric acid (mmol l1) 259.4 78.97 294.9 69.26
Serum albumin (g l1) 45.2 1.75a 43.6 2.23a
SGOT (U l1) 27.3 12.82 23.4 6.67
SGPT (U l1) 22.9 14.66 16.5 7.31
GGT (U l1) 16.5 8.67 16.7 8.92
Serum alkaline phosphatase (U l1) 661.7 204.30 684.9 196.65
Means followed by the same letters are significantly different at a: P<0.05, b: P<0.01 between the column,
respectively
Group 1: serum cholesterol level >5th percentile
Group 2: serum cholesterol level <5th percentile
Table 4 shows some clinical data and laboratory findings of the two groups as
follows:
 from the biomarkers relating to nutritional status, serum albumin was
significantly lower in patients with serum cholesterol below the 5th percentile value
(P<0.05),
 there was no significant difference between the values of the hepatic enzymes
and alkaline phosphatase,
 serum cholesterol, HDL-cholesterol, LDL-cholesterol, Apo A and Apo B
concentrations were significantly higher in group 1.
3. Discussion
The basis of cystic fibrosis is a mutation of the cystic fibrosis transmembrane
regulator (CFTR) gene located on the long arm of the 7th chromosome, resulting in the
inability of the CFTR protein in the plasma membrane of the epithelial cells to regulate
the cAMP stimulated chloride channels of the cell membrane. This results in the
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production of mucus with abnormal composition, which causes irreversible damage
primarily in the airways and the digestive system. Faultless functioning of the plasma
membrane necessitates adequate quantities of cholesterol (BÍRÓ, 1990.; IRIBARREN et
al., 1995.). This phenomenon call attention to the importance of our observation that a
considerable proportion of our patients treated for cystic fibrosis (60% in this study) the
serum levels of cholesterol were below the 5th percentile value, in spite of the fact that
the intake of fat, fatty acids and cholesterol - both in absolute value and per kg of body
weight  in these children was not less than that of the patients with cystic fibrosis with
serum cholesterol levels above the 5th percentile value.
We did not find any difference between the amount  which was in accordance
with the guidelines set for children with cystic fibrosis 35.6% of energy) (DODGE, 1992.,
MACDONALD, 1996)  or composition of the lipid intake of the two groups: SFAs,
MUFAs and PUFAs were approximately 11%, 11% and 8% of total energy,
respectively. Therefore we propose that the low levels of serum cholesterol were due to
a disorder in the endogenous cholesterol synthesis. Due to the parthomechanism of the
disease, this disorder can manifest in all patients with cystic fibrosis, as the lack of the
CFTR protein affects the epithelial cells of the liver and the biliary tract. Long-term
course of the disease lead to biliary cirrhosis, which can result in decreased levels of
cholesterol in multiple ways: decreased synthesis of cholesterol, and decrease in the
quantities of cholesterol salvaged via the entero-hepatic circulation (GYLLING et al.,
1995; MIETTIEN, 1972). Apo A and Apo B are the main components of HDL- and LDL-
cholesterol, respectively. The major sites of the synthesis of these proteins are the liver
and the intestine. It is a clear trend towards the low levels of total cholesterol and Apo A
reflecting the severity of liver injury. Moreover, the low Apo B concentration may be
connected to the impaired hepatic synthesis of this apolipoprotein (GRUNDY, 1999,
RIESEN & KLOER, 1989). Our data are in good accordance with these statements. It
should also be noted that treatment with modern enzyme products do not ensure perfect
absorption of fats, cholesterol and other nutrients (BERNABDESLAM et al., 1998,
KALIVIANAKIS et al., 1999).
We studied the levels of hepatic enzymes, serum alkaline phosphatase and found
no significant difference between the two groups. In other words we need a different
kind of parameter which is suitable for the evaluation of hepatic damage. For this reason
we suggest that the monitoring of serum cholesterol levels is an important and sensitive
method for all patients with cystic fibrosis.
We also investigated the importance of the high linoleic acid intake (EGMOND et
al., 1996) and the high ratio of linoleic to alfa-linolenic acid intake of our patients. An
increase in linoleic acid (n-6 PUFA) intake results in a lowering of plasma LDL-
cholesterol concentration. This effect may not be linear and most of the benefits appear
to be gained by moving from lower to moderate (~45% of energy) intake. Whereas a
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shift between 15 and 20% of energy as linoleic acid, is often without effect. Moreover, it
is worthy to note that the effects of dietary n-6 PUFAs are less than half of that of
lowering dietary saturated fatty acids. Therefore, if total fat intake is maintained, the
LDL-cholesterol lowering effects of increasing linoleic acid intake are greatly enhanced
if saturated fatty acid intake is decreased (HODGSON& WAHLQVIST, 1999). To maintain
the alveolar membrane integrity a sufficient docosahexaenoic acid (n-3, DHA C22:6)
content is absolutely necessary. When the ratio of linoleic to alfa-linolenic acid intake is
so high, the synthesis of DHA from alfa-linolenic acid is inhibited. So it would be
absolutely important to improve ratio of linoleic and alfa-linolenic acid with increasing
alfa-linolenic acid content of the diet of patients with cystic fibrosis (KATZ et al., 1996).
Summarizing our results it has been found that low serum cholesterol level with
adequate lipid, cholesterol intake and enzyme substitution implies an impaired
cholesterol absorption and/or hepatic lesion with connection to the severity of cystic
fibrosis. We would like to stress the importance of our finding, which shows a
significant correlation between low cholesterol levels and the Shwachman-Kulczycki
(SCHWACHMAN & KULCZYCKI, 1958) score, used since 1958 for the evolution of the
clinical status of patients with cystic fibrosis: children with decreased levels of
cholesterol have lower scores, their clinical condition is worse.
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